Insilicon Intelligent and Eli Lilly reach up to $2.75 billion AI drug research and development cooperation agreement

Insilicon Intelligent announced a cooperation agreement with Eli Lilly and Company of up to about $2.75 billion to use AI engines to accelerate the discovery and development of new therapies. The agreement includes a $115 million down payment and subsequent milestone payments and sales tiered royalties.